Navigation Links
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
Date:2/2/2009

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the BIO CEO and Investor Conference on Monday, February 9th, 2009 at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.

A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, pla
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... 2015 Biovista Inc. is glad ... 2015 BeHEARD science challenge, a global competition hosted by ... access to the latest life science innovations and technologies. ... pathway analytics capability to support Steven Laffoon ... study of Niemann-Pick Disease Type A (NPA), a rare ...
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate ... a prestigious Australian science prize recognising ,outstanding, science that ... track to globally launch a novel prostate cancer diagnostic ... a high level consortium taking out the peer-reviewed Australian ... Scientific Research. This prize is awarded ...
(Date:9/2/2015)... Israel , September 2, 2015 ... TASE: BOLT) ("BioLight" or the "Company"), a firm ... in ophthalmology and cancer diagnostics, announced today that ... of glaucoma will be delivered at the Ophthalmology ... the European Society of Cataract & Refractive Surgeons ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... of researchers has proposed a way to turn the material ... of electrons with a laser "on-off switch". Graphene is ... carbon atoms only one-atom thick, but 200 times stronger than ... than any other known material. It is almost completely transparent, ...
... June 17, 2011 Kendle International Inc. (Nasdaq: ... increased the consideration amount offered for its cash tender ... its $142.5 million aggregate principal amount of outstanding 3.375% ... No. US48880LAA52) (the "Notes").  The consideration for each $1,000.00 ...
... have been proposed for cell-based diagnostics and regenerative medicine ... develop into a desired cell type -- such as ... the clinical potential of these technologies. New research ... of the International Society for Stem Cell Research (ISSCR) ...
Cached Biology Technology:Graphene may gain an 'on-off switch,' adding semiconductor to long list of material's achievements 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/26/2015)... August 26, 2015 The report "Multi-Factor ... Five Factor), Application (Travel & Immigration, Government, Banking, Defense, ... Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market ... growing at a CAGR of 17.7% between 2015 and ... F igures spread through 169 P ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... presented at IAS build a compelling case for FUZEON ... the newest drugs to give patients facing resistance their ... treatment goal for all people living with HIV. , ... for all triple-class experienced patients. FUZEON combined with the ...
... A computer scientist at Washington University in St. Louis ... genome of a worm and has found 150 genes ... using the software, he and his colleagues have developed ... genes. , Michael Brent, Ph.D., Washington University professor of ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Newest HIV drugs should be used with FUZEON(R) 2Newest HIV drugs should be used with FUZEON(R) 3Program finds lost genes in nematode genome 2Program finds lost genes in nematode genome 3Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
... Clone/PAD: ZMD.366. Immunogen: ... internal region of human SENP1. ... human ~73 kDa SENP1. ... or DYKDDDDK)-HA-tagged-SENP1 transfected Hep2 cell ...
...
Biology Products: